Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
Martin J Coffey,1 Heleen H DeCory,2 Stephen S Lane31Pharmaceutical Product Development, Bausch and Lomb, Inc, Rochester, NY, USA; 2Global Medical Affairs, Pharmaceuticals, Bausch and Lomb, Inc, Rochester, NY, USA; 3Associated Eye Care, Stillwater, MN, USAAbstract: The eye has protective barriers (ie...
Guardado en:
Autores principales: | Coffey MJ, DeCory HH, Lane SS |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5bf698ef283d4c42ac60be0a97a3d826 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%)
por: Marlowe ZT, et al.
Publicado: (2013) -
Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies
por: Fong R, et al.
Publicado: (2019) -
A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
por: Khaimi MA
Publicado: (2018) -
Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery
por: Sheppard JD, et al.
Publicado: (2019) -
Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
por: Timothy L Comstock, et al.
Publicado: (2011)